


PHARMACEUTICAL 2019

CytomX Therapeutics Inc. Rank 115 of 371







PHARMACEUTICAL 2019

CytomX Therapeutics Inc. Rank 115 of 371



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is -51%, being 280% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	445,475
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	97,908
Liabilities, Non-Current	228,317
Other Assets	3,750
Other Compr. Net Income	1.0
Other Expenses	14,303
Other Liabilities	0
Other Net Income	7,573
Property and Equipment	6,934
Research and Development	103,866
Revenues	59,502
Selling, General and Administrative Expense	33,510

Output Variable	Value in 1000 USD
Assets	457,108
Liabilities	326,225
Expenses	151,679
Stockholders Equity	130,883
Net Income	-84,604
Comprehensive Net Income	-84,604
Economic Capital Ratio	-51%